ACE Group has launched an enhanced clinical trials liability proposition, which provides life science companies with specialist insurance for clinical trials programmes conducted anywhere in the world.
ACE Clinical Trials has been developed to offer timely and compliant cover as well as flexible solutions equally suitable for single trials and for large multinational multiple trial programmes.
The proposition is designed with pharmaceutical manufacturers, biotechnology organisations, medical device and equipment manufacturers, generics companies and research organisations in mind.
One of the main benefits of this increased cover is the introduction of fronting for large captive clinical trials programmes.
It will offer global casualty cover, including for the US, for UK-based life science companies, through ACE’s network and team of specialist life science and liability underwriters.
The cover will also have a flexible capacity of up to $75 million aggregated limit available per investigational product.
Mark Roberts, casualty manager for the UK and Ireland at ACE, said: “ACE Clinical Trials is another example of how ACE brings its specialist expertise and global experience to meet the needs of businesses.”
“With the experience of Claire Wilkinson, our in-house clinical trials expert based here in the UK and the strength of the ACE network of offices in 54 countries, clients can rest assured that their programmes will be compliant wherever they may be taking place.”
“Clinical trials are a key stage in the development of medicinal products and providing compliant cover and quick turnarounds ultimately benefits both patients and companies.”
